{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:16:37Z","timestamp":1778692597322,"version":"3.51.4"},"reference-count":106,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Background\/Objective: Follicular lymphoma (FL) is one of the most common indolent B-cell non-Hodgkin lymphomas (NHL) and is characterized by recurrent relapses despite advances in therapy. Bispecific antibodies that redirect T lymphocytes toward malignant B cells represent a major innovation in the treatment of relapsed or refractory disease. Mosunetuzumab is a CD20\u00d7CD3 bispecific antibody that induces T-cell mediated cytotoxicity against B-cell malignancies. In this manuscript, we describe the clinical experience with mosunetuzumab in three patients with relapsed or refractory FL treated at the Hospital Card. G. Panico, Tricase (LE). Methods: Clinical history, prior therapies, treatment responses, and safety outcomes are reported. Results: The cases illustrate the potential efficacy and manageable safety profile of mosunetuzumab in heavily pretreated FL patients. Conclusion: The effectiveness of this drug is confirmed in our center.<\/jats:p>","DOI":"10.3390\/antib15030040","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:26:37Z","timestamp":1778689597000},"page":"40","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico"],"prefix":"10.3390","volume":"15","author":[{"given":"Giulio","family":"Turco","sequence":"first","affiliation":[{"name":"Operative Complex Unit of Hospital Pharmacy Pia Fondazione di Culto e Religione Card. G. Panico, 73039 Tricase, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Tarantino","sequence":"additional","affiliation":[{"name":"Operative Complex Unit of Hospital Pharmacy Pia Fondazione di Culto e Religione Card. G. Panico, 73039 Tricase, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta Giuseppa","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Operative Complex Unit of Hospital Pharmacy Pia Fondazione di Culto e Religione Card. G. Panico, 73039 Tricase, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Greco","sequence":"additional","affiliation":[{"name":"Operative Complex Unit of Hematology Pia Fondazione di Culto e Religione Card. G. Panico, 73039 Tricase, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2726-0462","authenticated-orcid":false,"given":"Domenico","family":"Tricarico","sequence":"additional","affiliation":[{"name":"Hospital School of Pharmacy, Department of Pharmacy, Pharmaceutical Sciences, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zinzani, P.L., Mu\u00f1oz, J., and Trotman, J. (2024). Current and Future Therapies for Follicular Lymphoma, Springer.","DOI":"10.1186\/s40164-024-00551-1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_3","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [revised 4th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood.V91.11.4292","article-title":"Analysis of VH genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression","volume":"91","author":"Ottensmeier","year":"1998","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3960\/jslrt.23014","article-title":"The pathobiology of follicular lymphoma","volume":"63","author":"Carreras","year":"2023","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/353071a0","article-title":"Bcl-2 maintains B cell memory","volume":"353","author":"Hockenbery","year":"1991","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(89)90174-8","article-title":"Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation","volume":"57","author":"McDonnell","year":"1989","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.leu.2404426","article-title":"Molecular pathways in follicular lymphoma","volume":"21","author":"Bende","year":"2007","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2249.1993.tb05904.x","article-title":"Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis","volume":"91","author":"Lindhout","year":"1993","journal-title":"Clin. Exp. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","article-title":"Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma","volume":"25","author":"Glas","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2559.2010.03706.x","article-title":"The challenge of the microenvironment in B-cell lymphomas","volume":"58","author":"Coupland","year":"2011","journal-title":"Histopathology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/blood-2011-04-345777","article-title":"Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: A 3-D tissue-imaging study","volume":"118","author":"Laurent","year":"2011","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Roy","year":"2004","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","article-title":"Prognostic value of cellular proliferation and histologic grade in follicular lymphoma","volume":"85","author":"Martin","year":"1995","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A","article-title":"Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute","volume":"50","author":"Anderson","year":"1982","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2011.08596.x","article-title":"Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma","volume":"153","author":"Mercadal","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaophthalmol.2014.376","article-title":"Ocular adnexal follicular lymphoma: A multicenter international study","volume":"132","author":"Rasmussen","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.5858\/arpa.2018-0275-RA","article-title":"Update on gastrointestinal lymphomas","volume":"142","author":"Weindorf","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2012-05-429514","article-title":"Pediatric-type nodal follicular lymphoma: An indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement","volume":"120","author":"Louissaint","year":"2012","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2004.05046.x","article-title":"Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: A study from the Groupe d\u2019Etude des Lymphomes Folliculaires","volume":"126","author":"Canioni","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bjh.12675","article-title":"Peripheral blood involvement in patients with follicular lymphoma: A rare disease manifestation associated with poor prognosis","volume":"164","author":"Sarkozy","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_23","first-page":"1543","article-title":"Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region","volume":"148","author":"Flenghi","year":"1996","journal-title":"Am. J. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1096-9896(199606)179:2<145::AID-PATH565>3.0.CO;2-1","article-title":"BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin\u2019s lymphomas","volume":"179","author":"Pittaluga","year":"1996","journal-title":"J. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1182\/blood-2011-05-355255","article-title":"Follicular lymphoma in situ: Clinical implications and comparisons with partial involvement by follicular lymphoma","volume":"118","author":"Jegalian","year":"2011","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1182\/blood-2013-12-545954","article-title":"Human t(14;18)-positive germinal center B cells: A new step in follicular lymphoma pathogenesis?","volume":"123","author":"Tellier","year":"2014","journal-title":"Blood"},{"key":"ref_28","unstructured":"Yoshino, T., and Chott, A. (2019). Duodenal-type follicular lymphoma. WHO Classification of Tumours: Digestive System Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1200\/JCO.2010.32.9193","article-title":"Primary follicular lymphoma of the duodenum is a distinct mucosal\/submucosal variant of follicular lymphoma: A retrospective study of 63 cases","volume":"29","author":"Schmatz","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/annonc\/mdp557","article-title":"The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma","volume":"21","author":"Mori","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: First report of the National LymphoCare Study","volume":"27","author":"Link","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41375-020-01048-6","article-title":"Stage-specific trends in primary therapy and survival in follicular lymphoma: A nationwide population-based analysis in the Netherlands, 1989\u20132016","volume":"35","author":"Dinnessen","year":"2021","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare Study (NLCS): A prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.22.02327","article-title":"Randomized phase III trial evaluating subcutaneous rituximab for the first-line treatment of low-tumor burden follicular lymphoma: Results of a LYSA study","volume":"41","author":"Cartron","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"ref_43","first-page":"CD003805","article-title":"Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma","volume":"4","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","article-title":"Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_47","unstructured":"Brown, J.R., Freedman, A.S., Aster, J.C., Lister, A., and Connor, R.F. (2025). Treatment of Relapsed or Refractory Follicular Lymphoma, CRC Press."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/bloodadvances.2018016683","article-title":"Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: A systematic review and meta-analysis","volume":"2","author":"Yamshon","year":"2018","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"Klasa","year":"2006","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"Giurgea","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: Advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Chiu, M.L., Goulet, D.R., Teplyakov, A., and Gilliland, G.L. (2019). Antibody structure and function: The basis for engineering therapeutics. Antibodies, 8.","DOI":"10.3390\/antib8040055"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_58","unstructured":"(2026, February 09). Mosunetuzumab Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lunsumio-epar-product-information_en.pdf."},{"key":"ref_59","unstructured":"(2026, February 09). Mosunetuzumab-axgb Injection, for Intravenous Use. United States Prescribing Information. US Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf."},{"key":"ref_60","unstructured":"(2026, February 09). Epcoritamab-bysp Injection. US Food & Drug Administration (FDA) Approved Product Information. US National Library of Medicine, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2023.02.008","article-title":"Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study","volume":"178","author":"Park","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e00197","DOI":"10.1002\/prp2.197","article-title":"Molecular modeling of antibodies for the treatment of TNF\u03b1-related immunological diseases","volume":"4","author":"Pierri","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Mazzuoli, S., Tricarico, D., Demma, F., Furneri, G., and Guglielmi, F.W. (2016). Accelerated infliximab infusion: Safety, factors predicting adverse events, patients\u2019 satisfaction and cost analysis. A cohort study in IBD patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166443"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s12276-022-00870-5","article-title":"An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies","volume":"54","author":"Ko","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/BF00497778","article-title":"Modulation of rat skeletal muscle chloride channels by activators and inhibitors of protein kinase C","volume":"418","author":"Tricarico","year":"1991","journal-title":"Pflugers Arch."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nri2887","article-title":"Mechanisms for T cell receptor triggering","volume":"11","author":"Dushek","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"Zweegman","year":"2023","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","article-title":"Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy","volume":"146","author":"Huang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., and Qian, C. (2021). Bispecific antibodies: From research to clinical application. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.626616"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12957-022-02810-z","article-title":"High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer","volume":"20","author":"Mollavelioglu","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S1470-2045(15)00039-X","article-title":"Multifunctional receptor-targeting antibodies for cancer therapy","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., and Anzaghe, M. (2021). The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168947"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Koretzky","year":"2009","journal-title":"Annu Rev. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev.immunol.021908.132550","article-title":"Molecular basis of calcium signaling in lymphocytes: STIM and ORAI","volume":"28","author":"Hogan","year":"2010","journal-title":"Annu Rev. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0960-8966(01)00270-X","article-title":"Involvement of K(Ca2+) channels in the local abnormalities and hyperkalemia following the ischemia-reperfusion injury of rat skeletal muscle","volume":"12","author":"Tricarico","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/1871527320666210119095626","article-title":"ATP-sensitive Potassium Channel Subunits in Neuroinflammation: Novel Drug Targets in Neurodegenerative Disorders","volume":"21","author":"Maqoud","year":"2022","journal-title":"CNS Neurol. Disord. Drug. Targets"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Tricarico, D., Mele, A., Calzolaro, S., Cannone, G., Camerino, G.M., Dinardo, M.M., Latorre, R., and Conte Camerino, D. (2013). Emerging role of calcium-activated potassium channel in the regulation of cell viability following potassium ions challenge in HEK293 cells and pharmacological modulation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069551"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Steinhoff","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: Pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T-cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"mAbs"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Antonacci, M., Di Turi, A., Miciaccia, M., Denora, M., Maqoud, F., Perrone, M.G., Scilimati, A., and Tricarico, D. (2026). Actions of Midostaurin as Cation Channel and Tyrosine Kinase Inhibitor in Diffuse Intrinsic Pontine Glioma Cell Lines. Cancers, 18.","DOI":"10.3390\/cancers18071066"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Antonacci, M., Maqoud, F., Di Turi, A., Miciaccia, M., Perrone, M.G., Scilimati, A., and Tricarico, D. (2025). KATP Channel Inhibitors Reduce Cell Proliferation Through Upregulation of H3K27ac in Diffuse Intrinsic Pontine Glioma: A Functional Expression Investigation. Cancers, 17.","DOI":"10.3390\/cancers17030358"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e1576","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mech. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.2174\/138161208786369786","article-title":"Hypersensitivity reactions to last-generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use","volume":"14","author":"Calogiuri","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.21873\/anticanres.14062","article-title":"Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment","volume":"40","author":"Rombouts","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/cti.2015.14","article-title":"Clinical development methodology for infusion-related reactions with monoclonal antibodies","volume":"4","author":"Doessegger","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/TCRM.S204909","article-title":"The importance of early identification of infusion-related reactions to monoclonal antibodies","volume":"15","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Laforgia, M., Laface, C., Calabr\u00f2, C., Ferraiuolo, S., Ungaro, V., Tricarico, D., Gadaleta, C.D., Nardulli, P., and Ranieri, G. (2021). Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041980"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: A systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Cancemi, G., Campo, C., Caserta, S., Rizzotti, I., and Mannina, D. (2025). Single-agent and associated therapies with monoclonal antibodies: What about follicular lymphoma?. Cancers, 17.","DOI":"10.3390\/cancers17101602"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2412869","DOI":"10.1080\/2162402X.2024.2412869","article-title":"The landscape of T-cell engagers for the treatment of follicular lymphoma","volume":"13","author":"Landego","year":"2024","journal-title":"Oncoimmunology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"752098","DOI":"10.3389\/fphar.2022.752098","article-title":"Inflammatory Related Reactions in Humans and in Canine Breast Cancers, A Spontaneous Animal Model of Disease","volume":"13","author":"Tricarico","year":"2022","journal-title":"Front Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: A pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.22.00843","article-title":"Six-year results from RELEVANCE: Lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e2059","DOI":"10.6061\/clinics\/2021\/e2059","article-title":"Radiotherapy for early and advanced stages follicular lymphoma","volume":"76","author":"Mauro","year":"2021","journal-title":"Clinics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): A multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1115543","DOI":"10.3389\/fphar.2023.1115543","article-title":"Immunohistochemical, pharmacovigilance, and omics analyses reveal the involvement of ATP-sensitive K+ channel subunits in cancers: Role in drug-disease interactions","volume":"14","author":"Maqoud","year":"2023","journal-title":"Front Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.15720","article-title":"Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma","volume":"184","author":"Hill","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40164-021-00250-1","article-title":"Recent advances and challenges of bispecific antibodies in solid tumors","volume":"10","author":"Wu","year":"2021","journal-title":"Exp. Hematol. Oncol."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/3\/40\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:44:51Z","timestamp":1778690691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/3\/40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":106,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["antib15030040"],"URL":"https:\/\/doi.org\/10.3390\/antib15030040","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}